

Manuscript Number:

Title: The immune response regulates osteoclastogenesis and osteoinduction by submicrostructured beta-tricalcium phosphate.

Article Type: FLA Original Research

Section/Category: Biomaterials and Regenerative Medicine (BRM)

Keywords: Osteoinduction, Calcium Phosphate, Osteoclasts, Foreign Body Response, Osteoimmunology, Surface microstructure

Corresponding Author: Mr. Noel Davison, M.S.E.

Corresponding Author's Institution: Xpand Biotechnology BV

First Author: Noel Davison, M.S.E.

Order of Authors: Noel Davison, M.S.E.; Anne Laure Gamblin; Pierre Layrolle; Huipin Yuan; Joost D de Bruijn; Florence Barrere-de Groot

Abstract: Bone graft substitutes such as calcium phosphates interact with the immune system through the foreign body response, which may bear important consequences for bone regeneration. We speculate that the unique surface microarchitecture of osteoinductive beta-tricalcium phosphate (TCP) stimulates the differentiation of invading monocyte/macrophages into osteoclasts, and that these cells may be essential to ectopic bone formation. To test this, porous TCP cubes with either submicron-scale surface architecture known to induce ectopic bone formation (TCPs, positive control) or micron-scale surface architecture (TCPb, non-osteoinductive negative control) were subcutaneously implanted on the backs of FVB strain mice for 12 weeks. Additional TCPs samples received local, weekly injections of liposome-encapsulated clodronate (TCPs+LipClod) to deplete invading phagocytes. TCPs induced osteoclast formation, evident by positive tartrate resistant acid phosphatase (TRAP) cytochemical staining and negative macrophage membrane marker F4/80 immunostaining. No TRAP positive cells were found in TCPb or TCPs+LipClod, only F4/80 positive macrophages and foreign body giant cells. TCPs stimulated subcutaneous bone formation in all implants, while no bone could be found in TCPb or TCPs+LipClod. In agreement, expression of bone and osteoclast gene markers was up-regulated in TCPs versus either TCPb or TCPs+LipClod, which were equivalent. In summary, submicron-scale surface structure of TCP induced osteoclastogenesis and ectopic bone formation in a process dependent on an unhindered immune response.

AUTHOR DECLARATION LETTER

We the undersigned declare that this manuscript is original, has not been published before and is not currently being considered for publication elsewhere.

We wish to draw the attention of the Editor to the following facts which may be considered as potential conflicts of interest to this work: N Davison, H Yuan, F Barrere-de Groot, and JD de Bruijn all work for Xpand Biotechnology, a privately held company located in the Netherlands who manufactures and sells calcium phosphates as bone graft substitutes worldwide. JD de Bruijn and H Yuan are also shareholders of Xpand Biotechnology and Progentix Orthobiology BV

We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us.

We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication, with respect to intellectual property. In so doing we confirm that we have followed the regulations of our institutions concerning intellectual property.

We further confirm that any aspect of the work covered in this manuscript that has involved experimental animals has been conducted with the ethical approval of all relevant bodies and that such approvals are acknowledged within the manuscript.

We understand that the Corresponding Author is the sole contact for the Editorial process (including Editorial Manager and direct communications with the office). He/she is responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs. We confirm that we have provided a current, correct email address which is accessible by the Corresponding Author and which has been configured to accept email from biomaterials@online.be.

Signed by all authors as follows:

Noel Davison

Anne Laure Gamblin

Pierre Layrolle

Huipin Yuan

Joost D. de Bruijn

Florence Barrere-de Groot

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

The immune response regulates osteoclastogenesis and osteoinduction by submicrostructured beta-tricalcium phosphate.

Davison NL*^{1,2}, Gamblin AL³, Layrolle P³, Yuan H^{1,2}, de Bruijn JD^{1,2,4}, Barrere-de Groot F²

1 MIRA Institute, University of Twente, The Netherlands; 2 Xpand Biotechnology, The Netherlands; 3 INSERM UMR 957, University of Nantes, France; 4 Queen Mary University of London, United Kingdom

*Corresponding author: N.L.Davison@utwente.nl

1
2
3
4 **Abstract:** Bone graft substitutes such as calcium phosphates interact with the immune system through the
5
6 foreign body response, which may bear important consequences for bone regeneration. We speculate that
7
8 the unique surface microarchitecture of osteoinductive beta-tricalcium phosphate (TCP) stimulates the
9
10 differentiation of invading monocyte/macrophages into osteoclasts, and that these cells may be essential to
11
12 ectopic bone formation. To test this, porous TCP cubes with either submicron-scale surface architecture
13
14 known to induce ectopic bone formation (TCPs, positive control) or micron-scale surface architecture
15
16 (TCPb, non-osteoinductive negative control) were subcutaneously implanted on the backs of FVB strain
17
18 mice for 12 weeks. Additional TCPs samples received local, weekly injections of liposome-encapsulated
19
20 clodronate (TCPs+LipClod) to deplete invading phagocytes. TCPs induced osteoclast formation, evident by
21
22 positive tartrate resistant acid phosphatase (TRAP) cytochemical staining and negative macrophage
23
24 membrane marker F4/80 immunostaining. No TRAP positive cells were found in TCPb or TCPs+LipClod,
25
26 only F4/80 positive macrophages and foreign body giant cells. TCPs stimulated subcutaneous bone
27
28 formation in all implants, while no bone could be found in TCPb or TCPs+LipClod. In agreement,
29
30 expression of bone and osteoclast gene markers was up-regulated in TCPs versus either TCPb or
31
32 TCPs+LipClod, which were equivalent. In summary, submicron-scale surface structure of TCP induced
33
34 osteoclastogenesis and ectopic bone formation in a process dependent on an unhindered immune response.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1. Introduction

The capacity of the immune system to regulate bone homeostasis, ranging from pathological disorders such as bone metastases to normal fracture healing, forms the focus of osteoimmunology, a term that was coined only in 2000 [1]. The immune system is also the key player in orchestrating the host reaction to implanted biomaterials, i.e. the foreign body response [2]. At a nexus between the two fields, it is intriguing to consider that specific interactions with the immune system may be essential for the functional performance of bone graft substitutes to even further stimulate bone tissue regeneration in bony defects.

Following the evolving insight into biomaterial design [3], particular emphasis has been devoted to understanding how physical properties of CaP may influence their bone forming performance. For instance, implant geometry [4], 3D surface concavities [5,6], and interconnected porous structure [7] have all been shown to promote bone formation. Most recently, material surface architecture on the submicron and micron scale has been shown to be particularly important to the osteoinductivity of a small, unique subset of CaP through an unknown biological mechanism [8,9]. It is at this CaP-tissue interface where proteins and ions are absorbed and exchanged, as a function of the material surface reactivity and physico-chemistry [10]. On a cellular level, it is at this interface where invading leukocytes interact with the material surface, mediating inflammation and tissue repair during the host response [11].

It has been speculated that in the case of osteoinductive CaP, invading tissue macrophages triggered by the host response may play a role in osteogenesis because of

1
2
3
4 the dense and persistent presence of mononuclear cells surrounding an osteoinductive
5 implant without fibrous tissue formation [12,13]. On the other hand, an adverse host
6 response can also obstruct bone formation: in our previous work, chronic inflammation
7 due to the addition of a polymeric carrier completely abrogated ectopic bone formation
8 by osteoinductive beta-tricalcium phosphate (TCP) although the carrier dissolved
9 relatively quickly [14]. Indeed, macrophages, the principal cell responsible for clearing a
10 foreign body by phagocytosis, have been shown to express a distinct family of cytokines
11 depending on their activation state in response to material properties such as surface
12 chemistry, topography, and bioactivity [15,16].
13
14
15
16
17
18
19
20
21
22
23
24
25
26

27 Invading macrophages and other leukocytes secrete cytokines that can also spur
28 the fusion and specialization of bone-resorbing osteoclasts from their
29 monocyte/macrophage precursors. Pro-inflammatory cytokines such as TNF- α , IL-1, IL-
30 6, IFN-gamma, and PGE2 activate T-cell expression of soluble RANKL (receptor
31 activator of NF- κ B ligand) the essential osteoclast differentiation factor, as well as up-
32 regulate its membrane-bound receptor RANK on the surface of osteoclast precursors,
33 thus inducing osteoclastogenesis [17–20]. On the other hand, other secreted cytokines
34 such as IL-4 and IL-13 stimulate stromal cell expression of OPG (osteoprotegerin), the
35 natural decoy receptor to RANKL, thus antagonizing osteoclast differentiation [21]. In
36 this way, inflammation and osteoclastogenesis may be linked and dependent on the
37 precise cytokine cascade and a biomaterial substrate supporting pre-osteoclast fusion and
38 differentiation. Osteoclasts have also been implicated with the functionality of
39 osteoinductive CaP with reports that osteoclasts form prior to ectopic bone formation [22]
40 and that their inhibition may stunt osteoinduction [23,24].
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 Interestingly, macrophage-mediated inflammation has been associated with
5
6 pathological heterotopic ossification (HO) that results in marrow-containing bone
7
8 neogenesis in the muscle tissue triggered by injury. However, when liposome-
9
10 encapsulated bisphosphonate was locally administered to selectively deplete tissue
11
12 macrophages in a transgenic mouse model of HO, osteogenesis was significantly
13
14 blocked. This effect was attributed to the elimination of macrophage-secreted BMP4 at
15
16 the injury site [25]. In an experimental mouse model of osteoarthritis, macrophage
17
18 depletion, again by liposomal bisphosphonate, resulted in the reduction of osteophyte
19
20 formation – heterotopic bone nodules in the synovium – attributed to reduced
21
22 macrophage expression of osteogenic TGF β , BMP2, and BMP4. And as it pertains to the
23
24 natural regenerative capacity of bone, when macrophages were depleted using liposomal
25
26 clodronate in a long bone fracture model, bone formation in the fracture callus was fully
27
28 inhibited [26], shown elsewhere to be likely mediated by macrophage-expressed TNF- α
29
30 and IL-6 [27]. These studies and others like them emphasize the apparent importance of
31
32 macrophages and phagocyte relatives to both aberrant and reparative bone formation.
33
34
35
36
37
38
39
40
41

42 Importantly, both bone and immune cells have been shown to be highly sensitive
43
44 to surface microstructure of CaP. In our previous research investigating two TCP
45
46 ceramics with different sized surface features, both ectopic bone formation and the
47
48 presence of actively resorbing osteoclast-like multinucleated cells were strongly
49
50 promoted on *submicron-scale* TCP surface features (submitted article). On the other
51
52 hand, no ectopic bone and scarce non-resorbing multinucleated cells were found on the
53
54 TCP implants with *micron-scale* surface features. Following on these findings, we asked
55
56 whether these multinucleated cells were differentiated osteoclasts or merely fused
57
58
59
60
61
62
63
64
65

1
2
3
4 macrophages, i.e. foreign body giant cells, and whether they play a role in the resulting
5
6 ectopic bone formation by forming and functioning differently on the two different
7
8 topographies.
9

10
11
12 In order to investigate these questions, we implanted the same two TCP ceramics
13
14 with equivalent chemistry but different surface microstructure – serving as positive and
15
16 negative controls – in a recently validated mouse model of subcutaneous osteoinduction
17
18 [28] and analyzed the ectopic bone formation and the phenotype of formed
19
20 multinucleated cells using (immuno-)histological and gene expression analysis. To
21
22 address the role that these multinucleated cells play in osteoinduction, we applied
23
24 liposome-encapsulated clodronate (LipClod) to disrupt the host immune response and
25
26 selectively deplete invading phagocytic mononucleated precursor monocyte/macrophages
27
28 [29] and then evaluated ectopic bone formation.
29
30
31
32
33
34
35

36 **2. Materials and Methods**

37 38 39 *2.1 Preparation and Characterization of Porous TCP Cubes*

40
41
42
43 TCP powders were synthesized as previously described [14]. Briefly, calcium
44
45 hydroxide and phosphoric acid (both from Fluka) were mixed at a Ca/P ratio of 1.50.
46
47 TCP powders with small (TCPs) or big grains (TCPb) in the final ceramics were prepared
48
49 by controlling the reaction rates. The powders were foamed with diluted H₂O₂ (1%)
50
51 (Merck) at 60°C then dried at room temperature to get porous green bodies. The dry
52
53 green bodies were subsequently sintered at 1050°C or 1100°C for 8 hours to achieve
54
55 small and big grains for TCPs and TCPb, all respectively.
56
57
58
59
60
61
62
63
64
65

1
2
3
4 Porous cubes (4 x 4 x 4 mm) were machined from the ceramic bodies using a wet saw
5
6 and then ultrasonically cleaned in successive baths of acetone, ethanol, and distilled
7
8 water, and dried. Prior to implantation, TCP cubes were heat sterilized at 160°C for 2
9
10 hours. Crystal chemistry of the materials was analyzed by X-ray diffraction (Rigaku
11
12 Miniflex II) scanning the range $2\theta = 25\text{--}45^\circ$ (step size = 0.01° , rate = 1° min^{-1}) and
13
14 confirmed to be beta-TCP as previously described [14].
15
16
17
18
19

20 The TCP ceramics were characterized to confirm that they were composed of
21
22 different microstructure but similar macrostructure as previously reported (article
23
24 submitted). Surface microstructure was characterized by scanning electron microscopy
25
26 (SEM) (JEOL JSM-5600) after sputter coating with gold for 90 s (JEOL JFC 1300) and >
27
28 50 surface grains and micropores were measured in the using Image J image analysis
29
30 software (NIH, USA). To measure the surface profile (i.e., surface roughness), SEM
31
32 stereo-micrographs of the same location taken at two different tilt angles ($2500\times$, $\pm 5^\circ$)
33
34 were digitally reconstructed into three-dimensional surfaces for automated profile
35
36 analysis using MeX v5.1 software (Alicona Imaging, Austria). Additionally, porosity and
37
38 total pore area were determined by mercury intrusion testing (Table 1) (Micromeritics,
39
40 USA).
41
42
43
44
45
46
47

48 In summary, the synthesis of TCPs and TCPb resulted in submicron-scale and
49
50 micron-scale surface grains, micropores, and roughness, respectively. The ceramics
51
52 possessed similar total porosity but different total pore area owing to the smaller surface
53
54 features of TCPs.
55
56
57
58

59 2.2 *Subcutaneous implantation in FVB mice*

60
61
62
63
64
65

1
2
3
4 Ethical approval for animal experimentation was obtained from the local ethical
5
6 committee (CREEA). The animals were housed in certified premises at the Experimental
7
8 Therapeutic Unit at the Faculty of Medicine, University of Nantes, France. Animals were
9
10 stabled in cages with food and water *ad libidum* with artificial day/night cycle of 12 h and
11
12 regulated temperature of $20 \pm 1^\circ\text{C}$.
13
14
15

16
17
18 Five-week-old male FVB strain mice (n = 14) were received from Charles River
19
20 Laboratory (France) and allowed to equilibrate to their new surroundings for one week.
21
22 Prior to surgery, the mice were placed under general anesthesia using isoflurane gas (2.5
23
24 % in air, 2.5 l/min, Forene). Analgesic (Buprenorphine 60 $\mu\text{l}/\text{kg}$, Buprécare, MedVet)
25
26 was subcutaneously injected at the time of surgery and 1 day later. Backs of animals were
27
28 shaved and disinfected with iodine solution and sterile gauzes and covered with a surgical
29
30 sheet. Subcutaneous dorsal pockets were created using a scalpel and blunt nosed forceps
31
32 and one TCP cube was inserted per pocket. Skin incisions were tightly closed with
33
34 degradable sutures (Vicryl 4-0, Ethicon). Immediately following surgery, sterile
35
36 liposomal clodronate (100 μl) (Clodronate Liposomes Foundation, The Netherlands) was
37
38 injected into one pocket containing TCPs per animal. The same volume of sterile saline
39
40 was injected into one pocket containing TCPs and one containing TCPb per animal,
41
42 serving as positive and negative controls, respectively. This same injection regiment was
43
44 repeated once a week and then animals were sacrificed after 12 weeks by inhalation of an
45
46 overdose of carbon dioxide gas.
47
48
49
50
51
52
53

54
55 At this time, one long incision through the skin was made down the back and
56
57 carefully separated from the muscle using a scalpel. TCP implants were carefully cut
58
59
60
61
62
63
64
65

1
2
3
4 away from the soft tissue and skin and placed in vials containing either 4% formaldehyde
5
6 for histological analysis or in RNase/DNase free tubes containing 1 mL TRI® Reagent
7
8 (Sigma-Aldrich) for RNA isolation and qPCR. Histological replicates were stored at 4°C
9
10 for and qPCR replicates were frozen at -80°C for further processing.
11
12
13

14 2.3 *Histological Processing and imaging*

15
16
17
18
19 TCP explants from 9 mice were processed for histological analysis. Explants were
20
21 placed in cassettes and then decalcified in 4.13% EDTA/0.2% paraformaldehyde in PBS
22
23 (pH 7.4) at 50°C using an automated microwave decalcifying apparatus (KOS
24
25 Histostation, Milestone Med. Corp. MI, U.S.A). Samples were periodically checked with
26
27 x-ray to ensure complete and consistent decalcification, which required up to 17 days.
28
29
30 After complete decalcification, samples were then rinsed with tap water and dehydrated
31
32 in ascending series of ethanol baths: 80, 95, 100%, and finally in butanol for 30 min
33
34 (Automated dehydration station, Microm Microtech, France). Samples were then
35
36 impregnated in liquid paraffin at 56°C (Histowax) and embedded at -16°C. Embedded
37
38 explants were completely sectioned at 4-7 locations spaced ~500 µm using a standard
39
40 microtome (Leica RM2250) set at 5 um thickness. Following the various stains described
41
42 below, coverslips were mounted with Pertex and slides were digitally scanned at up to
43
44 40x magnification (NanoZoomer 2.0RS, Hamamatsu Corp. Japan) and analyzed with
45
46 virtual microscope software (NDP View, Hamamatsu Corp).
47
48
49
50
51
52
53

54 2.4 *Masson's Trichrome Staining for Bone Formation*

55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 Sections were stained by Masson's trichrome technique by using an automated
5
6 coloration station (Microm, Microtech). This staining combined hematoxylin for cell
7
8 nuclei in blue/black, fuchsin for cytoplasm, muscle and erythrocytes in red, and bright
9
10 green for collagen and allowed the visualization general tissue response and new bone
11
12 formation. Cover slips were mounted with Pertex and digitally scanned as previously
13
14 described. The presence of bone in each histological sample was carefully analyzed by
15
16 multiple researchers in at least 5 different sections taken at different levels throughout the
17
18 explant.
19
20
21
22
23

24 25 *2.5 Immunohistochemical Staining of Macrophage Marker F4/80 and Osteoblast* 26 27 *Transcription Factor Osterix* 28 29

30
31 Immunohistochemical staining of murine macrophage membrane marker F4/80
32
33 and osteoblast transcription factor Osterix served to identify macrophages and osteoblasts
34
35 in serial histological sections. Sections were first deparaffinized in Ottix histological
36
37 solvent (3 x 5 min), rehydrated in a graded ethanol series (100%, 3 x 5 min; 95%, 1 x 5
38
39 min; 80%, 1 x 5 min), and then rinsed in distilled water (3 x 5 min). To retrieve antigens,
40
41 sections were incubated in citrate buffer, pH 6, at 95°C for 10 min. Sections were then
42
43 incubated with 3% H₂O₂ for 15 min to inactivate endogenous peroxidase, rinsed with
44
45 TBS-Tween 0.05% pH 7.6, blocked with 5% normal goat serum in 1% BSA in TBS-
46
47 0.05% Tween pH 7.6 at room temperature for 30 min, then incubated at 4°C overnight
48
49 with primary antibodies (AbCAM) targeting F4/80 (rabbit anti-mouse monoclonal,
50
51 1:100) and sp7/Osterix (rabbit polyclonal, 1:800) diluted in blocking buffer. Sections
52
53 were again rinsed with TBS-Tween then incubated with secondary goat anti-rabbit
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 antibody (Dako) diluted 1:200 in blocking buffer for 30 min at RT, rinsed with TBS-
5
6 tween, incubated with streptavidin-linked HRP (Dako) for 30 min at RT, and finally
7
8 visualized with DAB chromogen (Dako) with Mayer's hematoxylin counterstain. Cover
9
10 slips were mounted with Pertex and digitally scanned as previously described.
11
12
13
14

15 2.6 *Cytochemical Staining of Osteoclast Enzyme Marker TRAP*

16
17
18

19 Cytochemical staining of osteoclast enzyme tartrate resistant acid phosphatase
20
21 (TRAP) was used as a marker to identify osteoclasts in histological sections. TRAP
22
23 staining was performed using a commercial staining kit (Acid Phosphatase Leukocyte
24
25 Staining Kit, Sigma) following the manufacturer's instructions. Briefly, staining solution
26
27 was prepared with Fast Red TR salt (3.9 mM), naphthol AS-TR phosphate disodium salt
28
29 (2.3 mM), N-N dimethylformamide (68 μ M), and L(+)-tartaric acid (100 mM) all diluted
30
31 in sodium acetate buffer (0.1 M, pH 5.2). Deparaffinized sections were incubated in the
32
33 solution for 90 min at 37°C and then counterstained with Mayer's hematoxylin. TRAP
34
35 positive stained cells appeared red.
36
37
38
39
40
41

42 2.7 *Gene expression by qPCR*

43
44
45

46 The gene expression of replicate TCP explants from 5 mice was analyzed by
47
48 qPCR. Frozen samples were thawed and thoroughly pulverized in TRI® Reagent (Sigma-
49
50 Aldrich) using a motorized pestle homogenizer. Samples were centrifuged to remove
51
52 TCP particles, and the RNA in the supernatant was precipitated in chloroform following
53
54 the manufacturer's instructions. Total RNA concentration and purity was measured using
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 a Nanodrop machine. Reverse transcription of cDNA was performed using a
5
6 ThermoScript First-Strand kit (Invitrogen).
7
8
9

10 Quantitative PCR (qPCR) was performed on a BioRad CFX 96 System. The PCR
11
12 reactions were performed with 20 ng cDNA in a total volume of 10 μ L containing iQ
13
14 SYBR Green Supermix (Biorad) and forward and reverse primers (300 nM). After an
15
16 initial activation step for 30 seconds at 98°C, 40 cycles were run of a two-step PCR
17
18 consisting of a denaturation step at 95°C for 15 seconds and annealing and extension step
19
20 at 60°C for 30 seconds. Subsequently the PCR products were subjected to melting curve
21
22 analysis to test if any unspecific PCR products were generated.
23
24
25
26
27

28 qPCR primers were designed using Primer-BLAST (www.ncbi.nlm.nih.gov)
29
30 spanning at least 1 intron to avoid amplification of genomic DNA (Table 3). Expression
31
32 of housekeeping genes HPRT and cyc1 was not affected by the experimental conditions
33
34 and were thus used for endogenous normalization of the gene targets. Relative fold
35
36 expression of the normalized gene targets was calculated versus expression levels in the
37
38 negative control, TCPb.
39
40
41
42
43

44 2.8 *Statistics*

45
46
47 Statistical comparisons of gene target expression were performed using One-way
48
49 ANOVA and Tukey's post hoc tests in GraphPad Prism 6.0 software. P values < 0.05
50
51 were considered significant.
52
53
54
55

56 3 **Results**

57
58
59
60
61
62
63
64
65

1
2
3
4 3.1 *Ectopic bone formation and tissue response*
5
6
7

8 TCPs and TCPb porous cubes were implanted in subcutaneous pockets on the
9
10 backs of mice and resulting ectopic bone formation was evaluated both by histological
11 and whole-sample gene expression analysis. During implantation some replicates
12 and whole-sample gene expression analysis. During implantation some replicates
13 intended for histological analysis were lost due to incomplete wound healing, particularly
14 intended for histological analysis were lost due to incomplete wound healing, particularly
15 for TCPs receiving LipClod treatment. After careful scrutiny of multiple random levels of
16 for TCPs receiving LipClod treatment. After careful scrutiny of multiple random levels of
17 each harvested sample, ectopic bone tissue could be identified in all of the TCPs explants
18 each harvested sample, ectopic bone tissue could be identified in all of the TCPs explants
19 (7 out of 7) and in none of the TCPb explants (0 out of 8), thus validating these materials
20 (7 out of 7) and in none of the TCPb explants (0 out of 8), thus validating these materials
21 as positive and negative controls in this model of osteoinduction. Importantly, no bone
22 as positive and negative controls in this model of osteoinduction. Importantly, no bone
23 was found in TCPs implants treated locally with LipClod (0 out of 5) to deplete the
24 was found in TCPs implants treated locally with LipClod (0 out of 5) to deplete the
25 invading phagocytes (Table 4).
26
27
28
29
30
31

32
33 In TCPs, bone formation was little in amount compared to the total implant area;
34 In TCPs, bone formation was little in amount compared to the total implant area;
35 however, cuboidal osteoblasts, osteocytes in characteristic lacunae, and multinucleated
36 however, cuboidal osteoblasts, osteocytes in characteristic lacunae, and multinucleated
37 osteoclast-like cells could all be identified. Moreover, a difference in the tissue response
38 osteoclast-like cells could all be identified. Moreover, a difference in the tissue response
39 was observed in that the pore structure of TCPs was generally occupied by darkly stained
40 was observed in that the pore structure of TCPs was generally occupied by darkly stained
41 highly condensed collagen fibrils whereas that of TCPb appeared to be lighter stained
42 highly condensed collagen fibrils whereas that of TCPb appeared to be lighter stained
43 loose connective tissue. In TCPs samples treated with LipClod, sparse connective tissue
44 loose connective tissue. In TCPs samples treated with LipClod, sparse connective tissue
45 in the pore structure appeared disorganized and did not stain the same dark, vivid green
46 in the pore structure appeared disorganized and did not stain the same dark, vivid green
47 as the dense collagen observed in TCPs control (Figure 1).
48 as the dense collagen observed in TCPs control (Figure 1).
49
50
51
52
53

54 Expression of mature bone markers BSP and OCL was significantly up-regulated
55 Expression of mature bone markers BSP and OCL was significantly up-regulated
56 in TCPs versus the negative control TCPb (~220 fold, P = 0.039; 3 fold, P = 0.0002;
57 in TCPs versus the negative control TCPb (~220 fold, P = 0.039; 3 fold, P = 0.0002;
58 respectively); however, expression levels in TCPs treated with LipClod were unchanged
59 respectively); however, expression levels in TCPs treated with LipClod were unchanged
60
61
62
63
64
65

1
2
3
4 versus TCPb (P = 0.930 and 0.999, respectively), substantiating the histological analysis
5
6 that LipClod treatment blocked bone formation by TCPs (Figure 1).
7
8
9

10 3.2 Identification of TRAP positive, F4/80 negative osteoclasts on TCP 11 12 13

14 Enzymatic staining for osteoclast marker TRAP served to identify osteoclasts in the
15 implants. Because mature osteoclasts are F4/80 negative [30–32], we compared TRAP
16 and F4/80 staining of the same multinucleated cells in serial sections in order to
17 unambiguously differentiate between multinucleated osteoclasts and fused macrophage
18 foreign body giant cells.
19
20
21
22
23
24
25
26

27 In TCPs, TRAP positive giant cells were located primarily between stretches of
28 ectopic bone attached to the material surface. In serial sections, these same cells were
29 confirmed to be F4/80 negative, establishing their identity as differentiated osteoclasts
30 rather than fused macrophages. Not all TRAP positive osteoclasts were located next to
31 bone suggesting that the presence of bone may not be necessary for their formation.
32 Moreover, not all multinucleated cells in TCPs were TRAP positive indicating the
33 heterogeneity of multinucleated cells throughout the explant. In contrast, TRAP positive
34 cells – either mononucleated or multinucleated – could not be found in neither TCPb nor
35 in TCPs treated with LipClod. The multinucleated cells colonizing these implants were
36 uniformly F4/80 positive.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

53 In support of the finding that TCPs promoted osteoclastogenesis while TCPb did
54 not, osteoclast gene markers TRAP, calcitonin receptor, and osteoclast transcription
55 factor NFATc1 were analyzed and indeed, these markers were significantly up-regulated
56
57
58
59
60
61
62
63
64
65

1
2
3
4 in TCPs (fold differences = 2, 234, and 1; P = 0.011, 0.021, and 0.046, all respectively).
5
6 In contrast, LipClod treatment left them unchanged versus TCPb (P = 0.564, 0.999, and
7
8 0.351, respectively). In an effort to explain these results, expression of the critical
9
10 osteoclast-signaling axis RANK-RANKL-OPG was analyzed, showing that RANK
11
12 expression was sharply down-regulated in TCPs + LipClod versus TCPs control (1.6
13
14 fold, P = 0.009), probably due to the selective eradication of phagocytic
15
16 monocyte/macrophage osteoclast precursors. The expression of RANKL and OPG were
17
18 also lower in TCPs after treatment with LipClod than without (0.9 and 1.1 fold
19
20 difference, respectively), although these differences were not significant (P = 0.152 and
21
22 0.105, respectively). Thus, the reason for osteoclast depletion may have been more due to
23
24 loss of RANK-expressing monocyte/macrophage osteoclast precursors rather than
25
26 alteration of the balance between RANKL and its decoy antagonist OPG.
27
28
29
30
31
32
33

34 *3.3 Macrophage colonization and depletion*

35
36
37
38 Macrophage-specific membrane marker F4/80 was visualized using
39
40 immunohistochemistry in order to evaluate the efficacy of LipClod treatment in depleting
41
42 phagocytic macrophages and foreign body giant cells characteristic of the foreign body
43
44 reaction. Indeed, LipClod treatment effectively depleted F4/80 positive cells particularly
45
46 at the outer surfaces of the implant accompanied by large numbers of negatively stained
47
48 mononuclear cells and cell fragments indicative of LipClod-initiated apoptosis. In
49
50 contrast, the outer edge of TCPs control was prominently lined with a dense layer of
51
52 F4/80 positive macrophages.
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 Despite the clear efficacy of macrophage depletion at the edge of the TCPs
5
6 implants, positively stained macrophages were still present in the inner pore structure,
7
8 similar to the untreated TCPs control. There in particular, F4/80 positive multinucleated
9
10 cells colonized the surface of TCPs regardless of LipClod treatment.
11
12
13
14

15 Positively stained macrophages were also present in TCPb, but appeared
16
17 substantially less organized than TCPs control. In particular, F4/80 positive macrophages
18
19 did not densely line the outer edge of TCPb as on TCPs control. In the pore structure,
20
21 however, F4/80 positive multinucleated cells were observed similar to TCPs with and
22
23 without LipClod treatment.
24
25
26
27

28 In support of these histological results, F4/80 gene expression was lower with
29
30 LipClod treatment versus TCPs control (0.7 fold difference), though not significantly
31
32 different ($P = 0.144$) confirming that F4/80 positive macrophage depletion was
33
34 incomplete. F4/80 expression was equivalent between TCPs and TCPb controls (0.2
35
36 fold difference), despite differences in staining intensity and organization.
37
38
39
40
41

42 *3.4 Osteoblast differentiation inhibited by phagocyte depletion*

43
44

45 To evaluate if LipClod treatment affected osteoblast differentiation associated
46
47 with osteoinduction by TCPs, immunohistochemical staining of Osterix confirmed the
48
49 presence of osteoblast-like cells in TCPs treated with LipClod, though less frequent than
50
51 in TCPs without treatment. Moreover, whereas Osterix positive cuboidal osteoblasts were
52
53 mainly located on or next to ectopic bone in the TCPs control, they were located in loose
54
55 connective tissue contained in the pore structure of TCPs + LipClod. No Osterix positive
56
57
58
59
60
61
62
63
64
65

1
2
3
4 cells were evident in TCPb (not shown). These histological results were substantiated by
5
6 significantly lower expression of osteoblast transcription factor Runx2 versus TCPs (2
7
8 fold, $P = 0.028$) and equivalent expression to TCPb ($P = 0.726$). Versus TCPb, Runx2
9
10 expression in the TCPs control was also higher, trending on statistical significance (1.5
11
12 fold, $P = 0.062$).
13
14
15

16 17 **4 DISCUSSION** 18 19

20
21 By identifying multinucleated cells that were positively stained for osteoclastic
22
23 enzyme TRAP but negatively stained for macrophage membrane marker F4/80 and vice
24
25 versa, the distinct presence of both OCl and FBGC were found on the surface of
26
27 osteoinductive submicrostructured TCPs in subcutaneous implants. Although FBGC
28
29 widely populated the surface of non-osteoinductive microstructured TCPb, no such
30
31 TRAP positive multinucleated cells could be found. Osteoclast markers were
32
33 significantly down-regulated on TCPb, suggesting that osteoclastogenesis is not common
34
35 to all CaP but is preferentially directed by osteoinductive surface microstructure. This
36
37 finding could provide an explanation for the widely varied and conflicting reports on the
38
39 identity of multinucleated cells surrounding different CaP in various implantation models
40
41 [33–36]: all CaP are not created equal; one material with a particular surface architecture
42
43 may promote osteoclastogenesis while another composed of the same chemistry and
44
45 macrostructure may not. In support of this finding, our previous work (article submitted)
46
47 demonstrated that TCPs promotes the formation and resorptive activity of OCl in vitro,
48
49 emphasizing the directive role of surface submicron surface structure on
50
51 osteoclastogenesis. It is interesting to consider that while biomaterials comprising a wide
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 range of material chemistries and structures trigger FBGC formation during the foreign
5
6 body response [2], an osteoinductive CaP material directs the formation of the three
7
8 major bone cells in a heterotopic location: OCl (multinucleated, F4/80 negative, TRAP
9
10 positive, residing on the material surface; Figure 2), osteoblasts (cuboidal, strongly
11
12 Osterix positive, residing on the bone surface; Figure 4), and osteocytes (weakly Osterix
13
14 positive, residing in bone lacunae; Figure 4).
15
16
17
18
19

20 In addition to this result, LipClod treatment impeded both bone formation and
21
22 osteoclastogenesis, substantiated by equivalent bone and osteoclast markers to the
23
24 negative non-osteoinductive control. Our hypothesis that the host response to
25
26 osteoinductive TCP may determine ectopic bone formation is therefore confirmed.
27
28 LipClod treatment was shown to potently deplete F4/80 positive macrophages around the
29
30 perimeter of the implants as intended; however, F4/80 positive mono- and multinucleated
31
32 cells could still be found in the internal pore structure of the implants. Moreover, F4/80
33
34 gene expression was not significantly down-regulated compared to non-treated controls.
35
36 Together, these results suggest that although LipClod treatment successfully depleted
37
38 invading macrophages at the implants' outer surface, the liposomes were unable to
39
40 substantially penetrate the inner pore structure thereby allowing macrophages migrating
41
42 from the internal vasculature to survive and proliferate. Nonetheless, LipClod treatment
43
44 evidently disrupted the normal phagocyte response enough to prevent bone and OCl
45
46 formation.
47
48
49
50
51
52
53
54

55 LipClod is extensively used in the literature to study the role of macrophages in
56
57 various disorders where inflammation and wound healing play a key role. The function
58
59
60
61
62
63
64
65

1
2
3
4 and efficacy of LipClod depletion of phagocytes, particularly macrophages, has been
5
6 thoroughly researched for over 20 years and is a strategy that has been used in more than
7
8 800 peer reviewed citations, attesting to its wide breadth of applications as a research tool
9
10 [37]. Mechanistically, when a clodronate-encapsulated liposome is phagocytosed, the
11
12 liposome is opened by intracellular lysozyme and the drug is released in the cytoplasm
13
14 where it is metabolized into a toxic ATP analog resulting in both apoptosis and necrosis
15
16 [38,39]. The specificity of LipClod in its ability to deplete only “professional”
17
18 phagocytes arises from the liposomes’ fast clearance time, the short half-life, non-toxicity
19
20 of free clodronate, and the inability of the liposomes to passively infiltrate the cell
21
22 membrane [29].
23
24
25
26
27
28
29

30 Expounding on the hypothesis that the host response to an osteoinductive implant
31
32 determines its osteogenic capacity, we speculated that the lack of multinucleated cells
33
34 such as OCl and FBGC would impede ectopic bone formation. This was further
35
36 supported by our previous observations in which the presence and resorptive activity of
37
38 these cells on implanted TCP was correlated with osteoinductivity. LipClod treatment
39
40 was selected to deplete these cells because it targets their mutual monocyte/macrophage
41
42 phagocyte precursors as well as OCl themselves. Although FBGC were still present in the
43
44 internal pore structure of the treated implants, no TRAP positive multinucleated cells
45
46 could be found in the treatment samples and OCl gene markers were significantly down-
47
48 regulated, suggesting that osteoclastogenesis or osteoclast survival was reduced. It is
49
50 unclear if OCl simply were unable to differentiate due to depleted levels monocyte-
51
52 macrophage precursors or whether OCl formed but then were directly depleted in the
53
54 same mechanism as macrophages – through phagocytosis of LipClod – as reported in the
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 literature [40,41]. A time course study might be useful in illuminating this question. In
5
6 either case, ectopic bone formation was impeded in the absence of depleted TRAP
7
8 positive OCl, although F4/80 positive mononuclear and multinucleated MP were still
9
10 present.
11
12
13
14

15 The question remains how phagocytes such as OCl or MP mediate ectopic bone
16
17 formation. Previous results from our group showed that when OCl and to a lesser extent
18
19 MP are cultured on osteoinductive TCP, they secrete soluble factors that potently induce
20
21 alkaline phosphatase enzyme activity in human mesenchymal stem cells without
22
23 osteogenic additives (article submitted). Other groups have described the secretion of
24
25 anabolic bone factors by both OCl and MP extensively as well. Most recently, osteoclast-
26
27 specific deletion of CTHRC1, a much sought after soluble bone coupling factor, was
28
29 shown to result in osteopenia in mice emphasizing the importance of osteoclast-secreted
30
31 anabolic factors on normal bone homeostasis [42]. Additionally, OCl have been reported
32
33 to secrete various other osteoblast differentiating factors such as bone morphogenetic
34
35 proteins (BMPs), sphingosine 1-phosphate (S1P), and Wnt10b [43–45]. Inflammatory
36
37 macrophages have also been demonstrated to secrete osteogenic factors such as
38
39 oncostatin M (OSM) [46,47] and may also express BMPs [48–50].
40
41
42
43
44
45
46
47

48 It has been suggested that macrophage-mediated inflammation may play a role in
49
50 osteoinduction by CaP though until now no experiments were conducted to specifically
51
52 target this cell type, nor have they shown a clear link between CaP-incited inflammation
53
54 and osteoinduction [12,13]. Omar et al. (2011) did, however, show that a titanium screw
55
56 coated with lipopolysaccharide (LPS) to stimulate classical activation of MP resulted in
57
58
59
60
61
62
63
64
65

1
2
3
4 higher bone contact when in orthotopic sites [51]. On the other hand, inflammation of this
5
6 sort has also been linked with osteolysis and poor osseointegration, which was
7
8 ameliorated with macrophage depletion [52], suggesting long-term catabolic effects on
9
10 bone rather than anabolic effects. Less clear yet is if inflammatory M1 and wound-
11
12 healing M2-polarized MP may influence the bone forming capacity of biomaterials such
13
14 as TCP differently. In sum, the results here substantiate the importance of MP in
15
16 osteoinduction, although it is unclear if they act directly on the differentiation and bone
17
18 secretion of osteoblasts or whether they mediate other cellular processes necessary for
19
20 osteoinduction such as differentiating into bone-promotive OCl or secreting vasculogenic
21
22 factors to increase blood flow and a supply of stem cells necessary for osteogenesis [27].
23
24
25
26
27
28
29

30 Interestingly, LipClod treatment also affected the expression of early osteoblast
31
32 markers Osterix and Runx2 in TCP compared to the control, in conjunction with no bone
33
34 formation and equivalent bone marker levels to non-inductive TCPb. One possible
35
36 explanation for this is that macrophages and osteoclasts secrete chemotactic signals such
37
38 as TNF- α , OSM, PDGF [45], and S1P that attract pre-osteoblasts. Another explanation
39
40 follows the potency of macrophage- and osteoclast-secreted anabolic factors to
41
42 differentiate stem cells directly. Thus, the role of these cells in osteoinduction may be to
43
44 first home mesenchymal stem cells to the implant site and then differentiate them into
45
46 osteoblasts by secreting anabolic trophic factors. It has been reported that osteoblast
47
48 markers are up-regulated in mesenchymal stem cells cultured on similarly osteoinductive
49
50 TCP [9], so the direct interaction of stem cells with an osteoinductive material may also
51
52 aid osteoblast formation. However, Osterix positive cells were observed without bone
53
54 formation suggesting that the activation of early osteoblast transcription factors may not
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 guarantee bone matrix secretion of mature osteoblasts without a normally functioning
5
6
7 phagocyte population.
8
9

10 Although the precise material parameters necessary for material-directed
11
12 osteoinduction remain unknown, the results presented here reinforce the importance of
13
14 surface microstructure and add to the growing understanding that the physical form of a
15
16 biomaterial surface can invoke profoundly different tissue responses [53–56]. Here, the
17
18 important role of surface microstructure was again emphasized in the disparate nature of
19
20 bone formation and bone marker expression between two TCP that differ in the scale of
21
22 their surface microarchitecture. By recapitulating the same bone incidence rate of these
23
24 TCP as previously described in a canine intramuscular model, the FVB mouse model of
25
26 subcutaneous osteoinduction recently reported by Barradas et al. (2012) was further
27
28 validated. Moreover, the application of weekly LipClod injections to locally deplete
29
30 invading MP at an implant surface also presents a useful strategy to evaluate the
31
32 importance of the host response to different material surfaces. Indeed, the sensitivity of
33
34 monocyte/macrophage-lineage cells to substrate topography alludes to an intriguing way
35
36 of controlling the foreign body response by modulating the scale of surface
37
38 microarchitecture. Indeed, the sensitivity of
39
40 monocyte/macrophage-lineage cells to substrate topography alludes to an intriguing way
41
42 of controlling the foreign body response by modulating the scale of surface
43
44 microarchitecture.
45
46

47 48 **5 Conclusion** 49

50
51 TCP with *submicron-scale* surface architecture was found to generate TRAP
52
53 positive, F4/80 negative OCl along with consistent ectopic bone formation in
54
55 subcutaneous pockets of mice but TCP with *micron-scale* surface architecture did not.
56
57 Liposomal Clodronate treatment, resulting in the complete depletion of TRAP positive,
58
59
60
61
62
63
64
65

1
2
3
4 F4/80 negative OC1 but not MP or FBGC, was found to block ectopic bone formation.
5
6
7 Thus, the scale of TCP surface architecture may be essential to ectopic bone formation by
8
9 directing the host response and subsequent osteoclastogenesis.
10

11 12 **Acknowledgements** 13

14
15
16 The authors gratefully acknowledge the support of the TeRM Smart Mix Program
17
18 of the Netherlands Ministry of Economic Affairs and the Netherlands Ministry of
19
20 Education, Culture and Science. This research forms part of the Project P2.04 BONE-IP
21
22 of the research program of the Biomedical Materials Institute, co-funded by the Dutch
23
24 Ministry of Economic Affairs. This work was also supported by funding under the
25
26 Seventh Research Framework Program of the European Union, through the project
27
28 REBORNE under Grant agreement no. 241879. Special thanks are due to Dr. Ana
29
30 Barradas (MIRA, University of Twente) for her generous consultation with the FVB
31
32 mouse model, and Jinyi Su (Xpand Biotechnology), Martine Berreur, and Jerome
33
34 Amiaud (both INSERM UMR957) for their help and technical expertise.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

References

- [1] Arron JR, Choi Y. Bone versus immune system. *Nature* 2000;408:535–6.
- [2] Anderson J, Rodriguez A, Chang D. Foreign Body Reaction to Biomaterials. *Semin Immunol* 2008;20:86–100.
- [3] Mitragotri S, Lahann J. Physical approaches to biomaterial design. *Nat Mater* 2009;8:15–23.
- [4] Magan A, Ripamonti U. Geometry of porous hydroxyapatite implants influences osteogenesis in baboons (*Papio ursinus*). *J Craniofac Surg* 1996;7:71–8.
- [5] Ripamonti U, Richter PW, Nilen RWN, Renton L. The induction of bone formation by smart biphasic hydroxyapatite tricalcium phosphate biomimetic matrices in the non-human primate *Papio ursinus*. *J Cell Mol Med* 2008;12:2609–21.
- [6] Habibovic P, Yuan H, van der Valk CM, Meijer G, van Blitterswijk C a, de Groot K. 3D microenvironment as essential element for osteoinduction by biomaterials. *Biomaterials* 2005;26:3565–75.
- [7] Yuan H, De Bruijn JD, Li Y, Feng J, Yang Z, De Groot K, et al. Bone formation induced by calcium phosphate ceramics in soft tissue of dogs: a comparative study between porous alpha-TCP and beta-TCP. *J Mater Sci Mater Med* 2001;12:7–13.
- [8] Habibovic P, Yuan H, van den Doel M, Sees TM, van Blitterswijk CA, de Groot K. Relevance of osteoinductive biomaterials in critical-sized orthotopic defect. *J Orthop Res* 2006;24:867–76.
- [9] Yuan H, Fernandes H, Habibovic P, de Boer J, Barradas AMC, de Ruiter A, et al. Osteoinductive ceramics as a synthetic alternative to autologous bone grafting. *Proc Natl Acad Sci U S A* 2010;107:13614–9.
- [10] Stevens MM, George JH. Exploring and engineering the cell surface interface. *Science* 2005;310:1135–8.
- [11] Eriksson C, Nygren H, Ohlson K. Implantation of hydrophilic and hydrophobic titanium discs in rat tibia: cellular reactions on the surfaces during the first 3 weeks in bone. *Biomaterials* 2004;25:4759–66.
- [12] Fellah BH, Josselin N, Chappard D, Weiss P, Layrolle P. Inflammatory reaction in rats muscle after implantation of biphasic calcium phosphate micro particles. *J Mater Sci Mater Med* 2007;18:287–94.

- 1
2
3
4 [13] Fellah BH, Delorme B, Sohier J, Magne D, Hardouin P, Layrolle P. Macrophage
5 and osteoblast responses to biphasic calcium phosphate microparticles. *J Biomed*
6 *Mater Res A* 2010;93:1588–95.
7
8
9 [14] Davison N, Yuan H, de Bruijn JD, Barrere-de Groot F. In vivo performance of
10 microstructured calcium phosphate formulated in novel water-free carriers. *Acta*
11 *Biomater* 2012;8:2759–69.
12
13
14 [15] Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation.
15 *Nat Rev Immunol* 2008;8:958–69.
16
17
18 [16] Jones JA, Chang DT, Meyerson H, Colton E, Kwon IK, Matsuda T, et al.
19 Proteomic analysis and quantification of cytokines and chemokines from
20 biomaterial surface-adherent macrophages and foreign body giant cells. *J Biomed*
21 *Mater Res A* 2007;83:585–96.
22
23
24 [17] Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the
25 immune and bone systems. *Nat Rev Immunol* 2007;7:292–304.
26
27
28 [18] Sima C, Glogauer M. Macrophage subsets and osteoimmunology: tuning of the
29 immunological recognition and effector systems that maintain alveolar bone.
30 *Periodontol* 2000 2013;63:80–101.
31
32
33 [19] Steeve KT, Marc P, Sandrine T, Dominique H, Yannick F. IL-6, RANKL, TNF-
34 alpha/IL-1: interrelations in bone resorption pathophysiology. *Cytokine Growth*
35 *Factor Rev* 2004;15:49–60.
36
37
38 [20] Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D. The molecular
39 triad OPG/RANK/RANKL: involvement in the orchestration of
40 pathophysiological bone remodeling. *Cytokine Growth Factor Rev* 2004;15:457–
41 75.
42
43
44 [21] Stein NC, Kreutzmann C, Zimmermann S-P, Niebergall U, Hellmeyer L, Goettsch
45 C, et al. Interleukin-4 and interleukin-13 stimulate the osteoclast inhibitor
46 osteoprotegerin by human endothelial cells through the STAT6 pathway. *J Bone*
47 *Miner Res* 2008;23:750–8.
48
49
50 [22] Kondo N, Ogose A, Tokunaga K, Umezu H, Arai K, Kudo N, et al. Osteoinduction
51 with highly purified beta-tricalcium phosphate in dog dorsal muscles and the
52 proliferation of osteoclasts before heterotopic bone formation. *Biomaterials*
53 2006;27:4419–27.
54
55
56 [23] Tanaka T, Saito M, Chazono M, Kumagae Y, Kikuchi T, Kitasato S, et al. Effects
57 of alendronate on bone formation and osteoclastic resorption after implantation of
58 beta-tricalcium phosphate. *J Biomed Mater Res A* 2010;93:469–74.
59
60
61
62
63
64
65

- 1
2
3
4 [24] Ripamonti U, Klar RM, Renton LF, Ferretti C. Synergistic induction of bone
5 formation by hOP-1, hTGF-beta3 and inhibition by zoledronate in macroporous
6 coral-derived hydroxyapatites. *Biomaterials* 2010;31:6400–10.
7
8
9 [25] Kan L, Liu Y, McGuire TL, Berger DMP, Awatramani RB, Dymecki SM, et al.
10 Dysregulation of local stem/progenitor cells as a common cellular mechanism for
11 heterotopic ossification. *Stem Cells* 2009;27:150–6.
12
13
14 [26] Alexander K a, Chang MK, Maylin ER, Kohler T, Müller R, Wu AC, et al. Osteal
15 macrophages promote in vivo intramembranous bone healing in a mouse tibial
16 injury model. *J Bone Miner Res* 2011;26:1517–32.
17
18
19 [27] Glass GE, Chan JK, Freidin A, Feldmann M, Horwood NJ, Nanchahal J. TNF-
20 alpha promotes fracture repair by augmenting the recruitment and differentiation
21 of muscle-derived stromal cells. *Proc Natl Acad Sci U S A* 2011;108:1585–90.
22
23
24 [28] Barradas AMC, Yuan H, van der Stok J, Le Quang B, Fernandes H, Chaterjea A,
25 et al. The influence of genetic factors on the osteoinductive potential of calcium
26 phosphate ceramics in mice. *Biomaterials* 2012;33:5696–705.
27
28
29 [29] Van Rooijen N, van Kesteren-Hendriks E. “In vivo” depletion of macrophages by
30 liposome-mediated “suicide”. *Methods Enzymol* 2003;373:3–16.
31
32
33 [30] Takahashi N, Udagawa N, Tanaka S, Murakami H, Owan I, Tamura T, et al.
34 Postmitotic osteoclast precursors are mononuclear cells which express
35 macrophage-associated phenotypes. *Dev Biol* 1994;163:212–21.
36
37
38 [31] Hume DA, Loutit JF, Gordon S. The mononuclear phagocyte system of the mouse
39 defined by immunohistochemical localization of antigen F4/80: macrophages of
40 bone and associated connective tissue. *J Cell Sci* 1984;66:189–94.
41
42
43 [32] Boyle W, Simonet W, Lacey D. Osteoclast differentiation and activation. *Nature*
44 2003;423:337–42.
45
46 [33] Wenisch S, Stahl J-P, Horas U, Heiss C, Kilian O, Trinkaus K, et al. In vivo
47 mechanisms of hydroxyapatite ceramic degradation by osteoclasts: fine structural
48 microscopy. *J Biomed Mater Res A* 2003;67:713–8.
49
50
51 [34] Dersot JM, Colombier ML, Lafont J, Baroukh B, Septier D, Saffar JL.
52 Multinucleated giant cells elicited around hydroxyapatite particles implanted in
53 craniotomy defects are not osteoclasts. *Anat Rec* 1995;242:166–76.
54
55
56 [35] Baslé MF, Chappard D, Grizon F, Filmon R, Delecrin J, Daculsi G, et al.
57 Osteoclastic resorption of Ca-P biomaterials implanted in rabbit bone. *Calcif*
58 *Tissue Int* 1993;53:348–56.
59
60
61
62
63
64
65

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- [36] Eggli PS, Müller W, Schenk RK. Porous hydroxyapatite and tricalcium phosphate cylinders with two different pore size ranges implanted in the cancellous bone of rabbits. A comparative histomorphometric and histologic study of bony ingrowth and implant substitution. *Clin Orthop Relat Res* 1988;127–38.
- [37] Van Rooijen N. The liposome-mediated macrophage “suicide” technique. *J Immunol Methods* 1989;124:1–6.
- [38] Metabolite A, Ylitalo K V, Mönkkönen J, Rogers MJ, Azhayev A, Kalervo HVA, et al. Further Insight into Mechanism of Action of Clodronate □ : Inhibition of Mitochondrial ADP / ATP Translocase by a. *Med Biochem* 2002;62:1255–62.
- [39] Frith JC, Mönkkönen J, Blackburn GM, Russell RG, Rogers MJ. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5’-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. *J Bone Miner Res* 1997;12:1358–67.
- [40] Wang W, Ferguson DJ, Quinn JM, Simpson AH, Athanasou NA. Osteoclasts are capable of particle phagocytosis and bone resorption. *J Pathol* 1997;182:92–8.
- [41] Frith JC, Mönkkönen J, Auriola S, Mönkkönen H, Rogers MJ. The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. *Arthritis Rheum* 2001;44:2201–10.
- [42] Takeshita S, Fumoto T, Matsuoka K, Park K, Aburatani H, Kato S, et al. Osteoclast-secreted CTHRC1 in the coupling of bone resorption to formation. *J Clin Invest* 2013;123:3914–24.
- [43] McCullough KA, Waits CA, Garimella R, Tague SE, Sipe JB, Anderson HC. Immunohistochemical localization of bone morphogenetic proteins (BMPs) 2, 4, 6, and 7 during induced heterotopic bone formation. *J Orthop Res* 2007;25:465–72.
- [44] Pederson L, Ruan M, Westendorf JJ, Khosla S, Oursler MJ. Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. *Proc Natl Acad Sci U S A* 2008;105:20764–9.
- [45] Kreja L, Brenner RE, Tautzenberger A, Liedert A, Friemert B, Ehrnthaller C, et al. Non-resorbing osteoclasts induce migration and osteogenic differentiation of mesenchymal stem cells. *J Cell Biochem* 2010;109:347–55.
- [46] Guihard P, Danger Y, Brounais B, David E, Brion R, Delecric J, et al. Induction of osteogenesis in mesenchymal stem cells by activated monocytes/macrophages depends on oncostatin m signaling. *Stem Cells* 2012;30:762–72.

- 1
2
3
4 [47] Nicolaidou V, Wong MM, Redpath AN, Ersek A, Baban DF, Williams LM, et al.
5 Monocytes induce STAT3 activation in human mesenchymal stem cells to
6 promote osteoblast formation. *PLoS One* 2012;7(7): e398:e39871.
7
8
9 [48] Champagne CM, Takebe J, Offenbacher S, Cooper LF. Macrophage cell lines
10 produce osteoinductive signals that include bone morphogenetic protein-2. *Bone*
11 2002;30:26–31.
12
13
14 [49] Honda Y, Anada T, Kamakura S, Nakamura M, Sugawara S, Suzuki O. Elevated
15 extracellular calcium stimulates secretion of bone morphogenetic protein 2 by a
16 macrophage cell line. *Biochem Biophys Res Commun* 2006;345:1155–60.
17
18
19 [50] Takebe J, Champagne CM, Offenbacher S, Ishibashi K, Cooper LF. Titanium
20 surface topography alters cell shape and modulates bone morphogenetic protein 2
21 expression in the J774A.1 macrophage cell line. *J Biomed Mater Res A*
22 2003;64:207–16.
23
24
25 [51] Omar OM, Granéli C, Ekström K, Karlsson C, Johansson A, Lausmaa J, et al. The
26 stimulation of an osteogenic response by classical monocyte activation.
27 *Biomaterials* 2011;32:8190–204.
28
29
30 [52] Ren W, Markel DC, Schwendener R, Ding Y, Wu B, Wooley PH. Macrophage
31 depletion diminishes implant-wear-induced inflammatory osteolysis in a mouse
32 model. *J Biomed Mater Res A* 2008;85:1043–51.
33
34
35 [53] Chen S, Jones J a, Xu Y, Low H-Y, Anderson JM, Leong KW. Characterization of
36 topographical effects on macrophage behavior in a foreign body response model.
37 *Biomaterials* 2010;31:3479–91.
38
39
40 [54] Zhang W, Wang G, Liu Y, Zhao X, Zou D, Zhu C, et al. Biomaterials The
41 synergistic effect of hierarchical micro / nano-topography and bioactive ions for
42 enhanced osseointegration. *Biomaterials* 2013;34:3184–95.
43
44
45 [55] Jäger M, Zilkens C, Zanger K, Krauspe R. Significance of Nano- and
46 Microtopography for Cell-Surface Interactions in Orthopaedic Implants. *J Biomed*
47 *Biotechnol* 2007;2007:1–19.
48
49
50 [56] Thomsen P, Gretzer C. Macrophage interactions with modified material surfaces.
51 *Curr Opin Solid State Mater Sci* 2001;5:163–76.
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure 1. Ectopic bone formation by TCPs and blockade by phagocyte depletion.

(Top) Representative sections stained with Masson's Trichrome from decalcified TCP (black stars) cubes subcutaneously implanted in mice for 12 weeks. Ectopic bone formation (white stars) was only found in TCPs (A, B), shown by dark green collagen staining. Osteocytes in lacunae (A, open arrows) and cuboidal osteoblasts (B, black arrows) can be seen in and on the mature bone matrix. Local liposomal clodronate injections blocked bone formation in TCPs (TCPs + LipClod) (C, D). Connective tissue in the pore space was generally less condensed (C, light green) though blood vessels were still formed (D, orange stained erythrocytes). TCPb (E, F) formed no bone although the pore structure was vascularized (E, orange erythrocytes) and cells had colonized the material surface (F, grey staining). 10x scale bar = 4 mm; 40x scale bar = 100 μ m. (Bottom) Gene expression of mature bone markers osteocalcin and bone sialoprotein were up-regulated in TCPs versus TCPs + LipClod and TCPb, while expression levels between TCPs + LipClod and non-inductive TCPb were equivalent. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.

Figure 2. Osteoclastogenesis by TCPs and depletion by Liposomal Clodronate.

(Top) Representative overview images (10x) stained with Masson's Trichrome show ectopic bone formation in TCPs (dark green) and not in TCPs treated with Liposomal Clodronate (LipClod) or non-inductive TCPb. (A, B) 40x insets of serial sections stained for osteoclast marker tartrate resistant acid phosphatase (TRAP) and macrophage membrane marker F4/80 show TRAP positive (red) F4/80 negative osteoclasts colonizing the material (black stars) between stretches of ectopic bone (white stars). No TRAP positive cells could be found in TCPs treated with Liposomal Clodronate (LipClod) (C, D) or the non-inductive TCPb (E, F). Multinucleated cells (black arrows) in these explants were uniformly F4/80 positive (brown) fused macrophages. 10x scale bar = 200 μ m; 40x scale bar = 100 μ m. (Bottom) Gene expression of osteoclast markers TRAP, CTR, and NFATc1 were significantly upregulated in TCPs versus TCPs + LipClod or TCPb. Expression of RANK was down-regulated in TCPs + LipClod versus TCPs, indicative of pre-osteoclast depletion. Expression levels of RANKL and its decoy receptor OPG varied between groups but were statistically equivalent. * $P < 0.05$, ** $P < 0.01$.

Figure 3. Macrophage colonization of TCP and depletion by Liposomal Clodronate.

(Top) Representative sections of TCP (black stars) immunohistochemically stained for macrophage membrane marker F4/80. F4/80 positive macrophages (brown) densely lined the (A) outer surface and (B) inner pore structure of TCPs, resembling osteal macrophages. Weekly liposomal Clodronate injections (TCPs + LipClod) effectively depleted F4/80 positivity at the (C) outer surface of TCPs with evident cell fragments indicative of apoptosis due to the treatment; however F4/80 positive macrophages still colonized the (D) inner pore structure. Positively stained macrophages less densely colonized the (E) outer surface and (F) inner pore structure of TCPb (TCP marked by black stars). 5x scale bar = 1 mm; 20x scale bar = 300 μ m. (Bottom) Gene expression of F4/80 was equivalent between all groups.

Figure 4. Osteoblast differentiation by TCPs is inhibited by phagocyte depletion.

(Top) Immunohistochemical staining of osteoblast marker Osterix in (left) Osterix positive cells (black arrows) were found colonizing the surface of TCPs (black stars) as well as bone tissue (white stars) containing osteocytes in lacunae (open arrows). (Right) Positively stained cells were also found in TCPs treated with Liposomal Clodronate (TCPs + LipClod) but to a lesser extent, both in the (top) inter-pore space and (bottom) in contact with the TCP surface, despite no bone formation. (Bottom) Gene expression of Runx2 was up-regulated in TCPs versus TCPs + LipClod, which was at an equivalent level as non-inductive TCPb. * $P < 0.05$.

Table 1. Physical characterization of TCP

Physical parameters	TCPs	TCPb
Average grain diameter	0.95 ± 0.27	3.66 ± 1.05
Average pore diameter	0.63 ± 0.33	1.78 ± 0.85
Average peak-to-valley roughness, R _a	0.126 ± 0.003	1.287 ± 0.011
Root-mean-square peak-to-valley roughness, R _{RMS}	0.158 ± 0.003	1.597 ± 0.011
Porosity (%)	69.6	72.0
Total pore area (m ² /g)	1.477	0.769

Table 2. qPCR primer sequences

Gene Target	Sequence (5' -> 3')	Product size (bp)	Accession ID
HPRT	tcctcctcagaccgcttt	90	NM_013556.2
	cctggttcatcatcgctaac		
Cyc1	tgtgctacacggaggaagaa	72	NM_025567.1
	catcatcattaggccatcc		
RANKL	tcctgtacttfcgagcgag	337	NM_011613.3
	ttatgggaacccgatgggatg		
CTK	ggaggcggctatatgacca	111	NM_007802.4
	ggcgtatacacaactttcatcc		
TRAP	cgtctctgcacagattgcat	75	NM_001102405.1
	aagcgcaaacggtagtaagg		
CTR	cctccagaggagaagaacc	95	NM_007588.2
	ggagattccgcctttcac		
OC	agactccggcgctacctt	86	NM_001032298.2
	caagcagggtaagtcaca		
RANK	tgcagctctccatgacactg	103	NM_009399.3
	cagccactactaccacagagatg		
OPG	atgaacaagtggtgtgctg	106	NM_008764.3
	cagtttctgggtcataatgcaa		
Runx2	ccacaaggacagagtcagattaca	92	NM_001145920.2
	tggctcagataggaggggta		
F4/80	tcctcctgcctggacact	100	NM_010130.4
	gccttgaaggcagcaacc		
NFATc1	catgagccatcatcga	130	NM_001164112.1
	tgggatgtgaactcggaagac		

Table 3. Incidence rate of ectopic bone formation by histological analysis.

TCPs	TCPs + LipClod	TCPb
7/7	0/5	0/8

Fig. 1





Fig. 2




Fig. 3





Fig 4

